Project description DEENESFRITPL Innovative urinary catheters to reduce infections and improve patients’ quality of life Urinary catheters (UC) are used during medical interventions and treatment, for incontinence or urine retention in cases of spinal cord injury, prostate hypertrophy and many other conditions. UC are associated with a decline in the patients’ quality of life, frequent emergency visits and increased risk of infection both for patients and health care professionals. The EU-funded T-CONTROL project is developing an improved UC with a novel design and a special hydrophobic membrane material to address shortfalls of currently available UC. The goal of the project includes the clinical validation of the added value, product registration and launch. Show the project objective Hide the project objective Objective T-Control is an innovative indwelling urinary catheter. Urinary Catheters (UC) are one of the most frequently used medical deviceson the market. They are used during medical interventions and treatment, as well as incontinence or urine retention in caseof spinal cord injury, prostate hypertrophy, weak muscle, and many other conditions. There are several unmet needs related to currently used catheters. They cause a sharp decline of quality of life of thepatients, are linked to frequent emergency visits and increase substentially the risk of infection both for patients and healthcare professionals. There are about 1,3 million cases in EU, causing 1,8 bn EUR direct cost and more than 14,000 deaths.T-Control is addressing all the previously mentioned problems thanks to its novel design and a special hydrophobic membrane material, with patent approval both in EU and US, developed after 4 years of R&D.T-Control will reduce additional days of hospitalization (leading to €1.14B savings in EU alone), but also guarantee the safety of health workers and decreasing continence related waste (sheets, gloves, diapers, catheters, bags…) representing around 29% of medical waste in non-acute hospitals. Rethink Medical SL develops new medical solutions, mainly linked to nursing. It raised the interest of 16 stakeholders on the market (Letters of Support).The feasibility study (SME Phase 1) shall address a financial plan, foreseeing all the costs and investments associated with commercializing our custom-made UC and the expected revenues. The study will also aim at assessing other important aspects such as IPR management, determine the best investment route for the growth stage, and conclude the best channels to reach customers and how we can best explain our difference from competition (prescribers, events, hospitals…). All these activities will lead to the ratification of a detailed business plan that will pave the way towards an effective market introduction. Fields of science medical and health scienceshealth sciencesnursingmedical and health sciencesclinical medicineurology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator RETHINK MEDICAL SL Net EU contribution € 50 000,00 Address C/ PRACTICANTE IGNACIO RODRIGUEZ S/N - EDIFICIO PO II DEL CAMPUS UNIVERSITARIO DE TAFIRA 35017 LAS PALMAS DE GRAN CANARIA Spain See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Canarias Canarias Gran Canaria Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00